ClinicalTrials.gg
RecruitingNCT07695935Updated Nov 20, 2026

Transversalis Fascia Plane Block Versus Low-Dose Intrathecal Morphine for Open Inguinal Hernia Repair

An interventional study of Intrathecal morphine and Ultrasound-guided transversalis fascia plane block in Postoperative Pain, sponsored by Hitit University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Hitit University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 17, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Pain, Postoperative by Hitit University — 4 open to participants now, 4 under way, none of them phase 3. Pain, Postoperative · Hitit University.

Planned enrollment
4th of 10
80 · median 74
Started
2026
with 3 others
No phase
10 of 10
4 open now
Registered
8th of 10
by date

Among the 10 studies in Pain, Postoperative by Hitit University, this one is the 4th largest by planned enrollment, is one of 4 that started in 2026, is one of 10 with no phase, and was the 8th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

4 of the 10 studies in Pain, Postoperative by Hitit University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pain, Postoperative by Hitit University, or all of them as a file.
02

Study summary

Open inguinal hernia repair is commonly associated with early postoperative pain, which may delay mobilization, reduce patient satisfaction, and increase opioid consumption. Low-dose intrathecal morphine may provide prolonged postoperative analgesia after spinal anesthesia; however, it may also be associated with opioid-related adverse effects such as nausea, vomiting, pruritus, urinary retention, sedation, and respiratory depression.

The transversalis fascia plane block is an ultrasound-guided fascial plane block that targets the sensory innervation of the lower abdominal wall, particularly the T12-L1 dermatomal region and the ilioinguinal and iliohypogastric nerve distribution. Although TFP block has been evaluated in lower abdominal procedures, direct comparison with low-dose intrathecal morphine in open inguinal hernia repair is limited.

This prospective, randomized, controlled, assessor-blinded trial aims to compare ultrasound-guided TFP block with low-dose intrathecal morphine in adult patients undergoing elective unilateral open inguinal hernia repair under spinal anesthesia. The primary outcome is total rescue opioid consumption during the first 24 postoperative hours. Secondary outcomes include pain scores at rest and with movement, time to first rescue analgesia, opioid-related adverse effects, quality of recovery, patient satisfaction, mobilization time, readiness for discharge, block success, sensory block distribution, and block-related complications.

Read the detailed description

Adult patients scheduled for elective unilateral open inguinal hernia repair under spinal anesthesia will be enrolled. After written informed consent, eligible patients will be randomly assigned in a 1:1 ratio to one of two groups.

In the intrathecal morphine group, patients will receive spinal anesthesia with 15 mg of 0.5% hyperbaric bupivacaine plus 100 mcg intrathecal morphine. No TFP block will be performed in this group.

In the TFP block group, patients will receive spinal anesthesia with 15 mg of 0.5% hyperbaric bupivacaine without intrathecal morphine. In addition, an ultrasound-guided unilateral TFP block will be performed on the surgical side before surgery using 30 mL of 0.25% bupivacaine, within the maximum safe dose limits.

All patients will receive a standardized multimodal postoperative analgesia protocol. Pain scores, rescue analgesic consumption, opioid-related adverse effects, quality of recovery, and safety outcomes will be recorded during the first 24 postoperative hours.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • Postoperative analgesia
  • Transversalis fascia plane block
  • Opioid consumption
  • Regional anesthesia
  • Intrathecal morphine
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18-80 years
  • Patients scheduled for elective unilateral open inguinal hernia repair
  • I-III
  • Patients planned to undergo spinal anesthesia
  • Patients able to understand and report postoperative pain scores
  • Patients who provide written

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • Bilateral inguinal hernia repair
  • Recurrent inguinal hernia repair
  • Emergency, incarcerated, or strangulated hernia
  • Need for general anesthesia
  • to spinal anesthesia
  • Coagulopathy or anticoagulant use contraindicating neuraxial or peripheral block
  • Infection at the injection site
  • Known allergy to local anesthetics, morphine, or study medications
  • Chronic opioid use
  • Preoperative chronic groin pain or neuropathic pain history
  • Severe hepatic or renal failure
  • Neurological or psychiatric condition preventing communication or pain assessment
  • Expected inability to complete postoperative follow-up
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Intrathecal Morphine Group

    Patients will receive spinal anesthesia with 15 mg of 0.5% hyperbaric bupivacaine plus 100 mcg intrathecal morphine. No TFP block will be performed.

    Drug: Intrathecal morphine

  • Experimental
    TFP Block Group

    An ultrasound-guided unilateral transversalis fascia plane block will be performed using 30 mL of 0.25% bupivacaine on the surgical side before open inguinal hernia repair. The local anesthetic dose will be adjusted according to patient weight and maximum safe dose limits.

    Procedure: Ultrasound-guided transversalis fascia plane block

Interventions

  • DrugMorphineStudies of MorphineMorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive 100 mcg intrathecal morphine in addition to 15 mg of 0.5% hyperbaric bupivacaine during spinal anesthesia.

  • ProcedureUltrasound-guided transversalis fascia plane block

    Patients will receive an ultrasound-guided unilateral transversalis fascia plane block on the surgical side using 30 mL of 0.25% bupivacaine before surgery.

06

What researchers measure

Primary outcomes

  1. Total Rescue Opioid Consumption During the First 24 Postoperative Hours

    Total rescue opioid analgesic consumption during the first 24 postoperative hours will be recorded and converted to intravenous morphine equivalents.

    Time frame: 0-24 hours after surgery

Secondary outcomes

  1. Quality of Recovery Score

    Quality of recovery will be assessed using the QoR-15 score. The total score ranges from 0 to 150, with higher scores indicating better recovery.

    Time frame: 24 hours after surgery

  2. Opioid-Related Adverse Effects

    Nausea, vomiting, pruritus, urinary retention, sedation, respiratory depression, and oxygen desaturation will be recorded.

    Time frame: 0-24 hours after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 5 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Oct 2026 → Dec 2026 and completion Nov 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 10, 2026
StartActual
Jun 8, 2026
Primary completionEst.
Dec 1, 2026was Oct 2026
CompletionEst.
Dec 10, 2026was Nov 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 23, 2026→Jun 8, 2026
Nov 17, 2026
Primary completion
Oct 23, 2026→Dec 1, 2026
Nov 17, 2026
Study completion
Nov 1, 2026→Dec 10, 2026
Nov 17, 2026
Show all 2 updates
  1. Nov 20, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 17, 2026
    Start date Jun 23, 2026→Jun 8, 2026
    Primary completion Oct 23, 2026→Dec 1, 2026
    Study completion Nov 1, 2026→Dec 10, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07695935
Lead sponsor
Hitit University
Responsible party
Sibel Onen Ozdemir (Principal Investigator, Hitit University) — Principal investigator
First posted
Jul 10, 2026
Start date
Jun 8, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 10, 2026 (estimated)
Last update
Nov 20, 2026

Study contacts

Sibel Onen Ozdemir, MD
Contact
sibelonen89@gmail.com
+905442892194

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion